As someone already said - rapamycin literature is mostly in cancer and transplant patients and with relatively high-doses. The risks are real, but my clinical judgement would lead me to believe that for at least some people the benefits would far outweigh the risks

One of the big confounders there is that it typically is given to people undergoing chemotherapy, not otherwise generally healthy people.